Sentien Biotechnologies Announces Open IND in Phase 1/2 Trial of SBI-101 for Patients with COVID-19
Filter: PRESS RELEASES IN THE NEWS EVENTS
Sentien Biotechnologies Announces Open IND in Phase 1/2 Trial of SBI-101 for Patients with COVID-19
LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for the evaluation of Sentien’s lead asset, SBI-101, for the treatment of severe COVID-19. Approval of this IND allows Sentien to initiate a Phase 1/2 study with a focus on COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) requiring renal replacement therapy (RRT).